No connection

Search Results

ANIP vs IMCR

ANIP
ANI Pharmaceuticals, Inc.
BEARISH
Price
$70.49
Market Cap
$1.58B
Sector
Healthcare
AI Confidence
85%
IMCR
Immunocore Holdings plc
BEARISH
Price
$31.05
Market Cap
$1.57B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ANIP
21.23
IMCR
--
Forward P/E
ANIP
6.82
IMCR
-22.02
P/B Ratio
ANIP
2.73
IMCR
4.13
P/S Ratio
ANIP
1.79
IMCR
3.94
EV/EBITDA
ANIP
10.33
IMCR
-51.28

Profitability

Gross Margin
ANIP
61.36%
IMCR
96.53%
Operating Margin
ANIP
11.99%
IMCR
0.03%
Profit Margin
ANIP
8.87%
IMCR
-8.88%
ROE
ANIP
16.16%
IMCR
-9.58%
ROA
ANIP
3.82%
IMCR
-1.54%

Growth

Revenue Growth
ANIP
29.6%
IMCR
24.3%
Earnings Growth
ANIP
--
IMCR
--

Financial Health

Debt/Equity
ANIP
1.16
IMCR
1.15
Current Ratio
ANIP
2.71
IMCR
4.04
Quick Ratio
ANIP
2.07
IMCR
3.91

Dividends

Dividend Yield
ANIP
--
IMCR
--
Payout Ratio
ANIP
0.0%
IMCR
0.0%

AI Verdict

ANIP BEARISH

ANIP's Piotroski F-Score of 4/9 indicates weak financial health, falling short of the stable threshold and signaling potential operational inefficiencies. The absence of an Altman Z-Score raises concern about bankruptcy risk, especially given a high debt/equity ratio of 1.16. Despite strong revenue growth (29.6% YoY) and solid gross margins (61.36%), the stock trades at a premium to its intrinsic value, with a current price of $70.49 versus a Graham Number of $43.90 and intrinsic value of $23.24. Insider selling activity totaling $3.39M in the last six months further undermines confidence, while technical trends remain bearish. Analysts remain optimistic with a $110.62 target, but this may reflect overvaluation given the underlying financial and sentiment risks.

Strengths
Strong revenue growth of 29.6% YoY
High gross margin of 61.36%
Solid operating margin of 11.99%
Risks
Piotroski F-Score of 4/9 indicates weak financial health
No Altman Z-Score available, raising potential bankruptcy risk
Insider selling activity totaling $3.39M in last 6 months
IMCR BEARISH

IMCR exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor financial health and operational deterioration. While the company maintains an impressive gross margin of 96.53% and positive revenue growth of 24.3%, these are offset by a catastrophic year-over-year EPS decline of 452.9% and a bearish insider sentiment. There is a stark disconnect between the aggressive analyst target price of $63.86 and the actual deterministic data, which suggests a high-risk profile characterized by consistent earnings misses and insider liquidation.

Strengths
Exceptional gross margins (96.53%) typical of high-value biotech products
Strong short-term liquidity with a current ratio of 4.04
Consistent positive revenue growth (24.3% YoY)
Risks
Critical financial health failure (Piotroski F-Score 1/9)
Severe earnings collapse with YoY EPS growth of -452.9%
Bearish insider activity with $4.35M in sales and zero buys

Compare Another Pair

ANIP vs IMCR: Head-to-Head Comparison

This page compares ANI Pharmaceuticals, Inc. (ANIP) and Immunocore Holdings plc (IMCR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile